A scorecard of progress towards measles elimination in 15 west African countries, 2001-19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data.
Africa, Western
Disease Eradication
/ statistics & numerical data
Humans
Immunization Programs
/ statistics & numerical data
Immunization Schedule
Infant
Measles
/ prevention & control
Measles Vaccine
/ administration & dosage
Population Surveillance
Retrospective Studies
Vaccination Coverage
/ statistics & numerical data
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
27
04
2020
revised:
16
10
2020
accepted:
28
10
2020
pubmed:
20
2
2021
medline:
10
3
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
The WHO Regional Office for the Africa Regional Immunization Technical Advisory Group, in 2011, adopted the measles control and elimination goals for all countries of the African region to achieve in 2015 and 2020 respectively. Our aim was to track the current status of progress towards measles control and elimination milestones across 15 west African countries between 2001 and 2019. We did a retrospective multicountry series analysis of national immunisation coverage and case surveillance data from Jan 1, 2001, to Dec 31, 2019. Our analysis focused on the 15 west African countries that constitute the Economic Community of West African States. We tracked progress in the coverage of measles-containing vaccines (MCVs), measles supplementary immunisation activities, and measles incidence rates. We developed a country-level measles summary scorecard using eight indicators to track progress towards measles elimination as of the end of 2019. The summary indicators were tracked against measles control and elimination milestones. The weighted average regional first-dose MCV coverage in 2019 was 66% compared with 45% in 2001. 73% (11 of 15) of the west African countries had introduced second-dose MCV as of December, 2019. An estimated 4 588 040 children (aged 12-23 months) did not receive first-dose MCV in 2019, the majority (71%) of whom lived in Nigeria. Based on the scorecard, 12 (80%) countries are off-track to achieving measles elimination milestones; however, Cape Verde, The Gambia, and Ghana have made substantial progress. Measles will continue to be endemic in west Africa after 2020. The regional measles incidence rate in 2019 was 33 times the 2020 elimination target of less than 1 case per million population. However, some hope exists as countries can look at the efforts made by Cape Verde, The Gambia, and Ghana and learn from them. None.
Sections du résumé
BACKGROUND
The WHO Regional Office for the Africa Regional Immunization Technical Advisory Group, in 2011, adopted the measles control and elimination goals for all countries of the African region to achieve in 2015 and 2020 respectively. Our aim was to track the current status of progress towards measles control and elimination milestones across 15 west African countries between 2001 and 2019.
METHODS
We did a retrospective multicountry series analysis of national immunisation coverage and case surveillance data from Jan 1, 2001, to Dec 31, 2019. Our analysis focused on the 15 west African countries that constitute the Economic Community of West African States. We tracked progress in the coverage of measles-containing vaccines (MCVs), measles supplementary immunisation activities, and measles incidence rates. We developed a country-level measles summary scorecard using eight indicators to track progress towards measles elimination as of the end of 2019. The summary indicators were tracked against measles control and elimination milestones.
FINDINGS
The weighted average regional first-dose MCV coverage in 2019 was 66% compared with 45% in 2001. 73% (11 of 15) of the west African countries had introduced second-dose MCV as of December, 2019. An estimated 4 588 040 children (aged 12-23 months) did not receive first-dose MCV in 2019, the majority (71%) of whom lived in Nigeria. Based on the scorecard, 12 (80%) countries are off-track to achieving measles elimination milestones; however, Cape Verde, The Gambia, and Ghana have made substantial progress.
INTERPRETATION
Measles will continue to be endemic in west Africa after 2020. The regional measles incidence rate in 2019 was 33 times the 2020 elimination target of less than 1 case per million population. However, some hope exists as countries can look at the efforts made by Cape Verde, The Gambia, and Ghana and learn from them.
FUNDING
None.
Identifiants
pubmed: 33607028
pii: S2214-109X(20)30481-2
doi: 10.1016/S2214-109X(20)30481-2
pmc: PMC7900524
pii:
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e280-e290Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MC_UP_A900/115
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A900/1122
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Science. 2015 Mar 13;347(6227):1240-2
pubmed: 25766232
Infect Dis Poverty. 2015 Feb 24;4:13
pubmed: 25737782
Glob Health Action. 2014 Oct 10;7:25287
pubmed: 25308818
Pan Afr Med J. 2017 Jun 21;27(Suppl 3):13
pubmed: 29296148
Asian Pac J Trop Med. 2013 Feb;6(2):131-4
pubmed: 23339915
Confl Health. 2019 Oct 29;13:49
pubmed: 31673285
BMJ Glob Health. 2019 Sep 6;4(5):e001713
pubmed: 31565416
Health Policy Plan. 2014 Mar;29(2):193-203
pubmed: 23426974
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
Bull World Health Organ. 2017 Feb 1;95(2):128-134
pubmed: 28250513
J Immunol Sci. 2018 Jul 28;Suppl:113-121
pubmed: 30766972
Vaccine. 2018 Jan 11;36 Suppl 1:A1-A34
pubmed: 29307367
Expert Rev Anti Infect Ther. 2015;13(11):1299-301
pubmed: 26489536
J Infect Dis. 2019 Nov 6;220(12):1870-1872
pubmed: 30615164
Lancet Infect Dis. 2017 Dec;17(12):e420-e428
pubmed: 28757186
MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1105-1111
pubmed: 31805033
Science. 2019 Nov 1;366(6465):599-606
pubmed: 31672891
J Immunol Sci. 2018 Aug 2;Suppl:130-134
pubmed: 30957101